2020
DOI: 10.4103/ijpn.ijpn_25_20
|View full text |Cite
|
Sign up to set email alerts
|

Central sensitization and its role in chronic pain: What can ketamine do?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 22 publications
0
1
0
1
Order By: Relevance
“…The intranasal route of ketamine administration has several advantages. A large surface area, high permeability and extensive vascularisation of the nasal mucosa cause rapid absorption of the drug [30]. In a cross-over trial, ketamine was administered intranasally to 20 patients with breakthrough pain, randomly assigned to groups receiving 10-50 mg of ketamine (patient-controlled dose) or placebo -in 45% of patients treated with ketamine, pain intensity was reduced by 40% or more, compared to 5% in the placebo group (p = 0.0078) [31].…”
Section: Intranasal Routementioning
confidence: 99%
See 1 more Smart Citation
“…The intranasal route of ketamine administration has several advantages. A large surface area, high permeability and extensive vascularisation of the nasal mucosa cause rapid absorption of the drug [30]. In a cross-over trial, ketamine was administered intranasally to 20 patients with breakthrough pain, randomly assigned to groups receiving 10-50 mg of ketamine (patient-controlled dose) or placebo -in 45% of patients treated with ketamine, pain intensity was reduced by 40% or more, compared to 5% in the placebo group (p = 0.0078) [31].…”
Section: Intranasal Routementioning
confidence: 99%
“…Donosową drogę podania ketaminy cechuje kilka zalet. Znaczna powierzchnia, wysoka przepuszczalność i rozległe unaczynienie błony śluzowej nosa powodują szybkie wchłanianie leku [30]. W badaniu krzyżowym ketaminę podawano drogą donosową 20 chorym z bólem przebijającym, losowo przydzielonych do grup otrzymujących 10-50 mg ketaminy (dawka kontrolowana przez pacjenta) lub placebo -u 45% chorych leczonych ketaminą uzyskano zmniejszenie natężenia bólu o 40% lub więcej, w porównaniu z 5% w grupie otrzymującej placebo (p = 0,0078) [31].…”
Section: Droga Donosowaunclassified